Publications by authors named "Alice Shaw"

Claim this Profile
R
Response and Resistance to RAS Inhibition in Cancer.
Richard Y Ebright, Julien Dilly, Alice T Shaw, Andrew J Aguirre

Cancer Discov· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer.
Biagio Ricciuti, Francesca Fusco, Alissa Cooper, Edoardo Garbo, Federica Pecci, Alice T Shaw

JAMA Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
Young lung cancer: from diagnosis to survivorship.
Narjust Florez, Lauren Kiel, Rebekah Kaufman, Jaclyn LoPiccolo, Biagio Ricciuti, Alice T Shaw

Front Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun, Alice T Shaw

Nature· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB study.
Ibiayi Dagogo-Jack, Alissa J Cooper, Bruce E Johnson, Justin F Gainor, Jessica J Lin, Alice T Shaw

Lung Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer.
Benjamin J Solomon, Geoffrey Liu, Enriqueta Felip, Tony S K Mok, Ross A Soo, Alice T Shaw

Future Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun, Alice T Shaw

Nature· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lorlatinib Versus Crizotinib in Patients With Advanced -Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.
Benjamin J Solomon, Geoffrey Liu, Enriqueta Felip, Tony S K Mok, Ross A Soo, Alice T Shaw

J Clin Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer.
Joseph Chen, Alessandra Bearz, Dong-Wan Kim, Hirva Mamdani, Jessica Bauman, Alice T Shaw

Clin Pharmacokinet· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC.
Ross A Soo, Jean-François Martini, Anthonie J van der Wekken, Shunsuke Teraoka, Roberto Ferrara, Alice T Shaw

J Thorac Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.
Alessandra Bearz, Jean-François Martini, Jacek Jassem, Sang-We Kim, Gee-Chen Chang, Alice T Shaw

J Thorac Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy-induced APOBEC3A drives evolution of persistent cancer cells.
Hideko Isozaki, Ramin Sakhtemani, Ammal Abbasi, Naveed Nikpour, Marcello Stanzione, Alice T Shaw

Nature· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.
Arvind Ravi, Matthew D Hellmann, Monica B Arniella, Mark Holton, Samuel S Freeman, Alice T Shaw

Nat Genet· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.
Benjamin J Solomon, Todd M Bauer, Tony S K Mok, Geoffrey Liu, Julien Mazieres, Alice T Shaw

Future Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
Benjamin J Solomon, Todd M Bauer, Tony S K Mok, Geoffrey Liu, Julien Mazieres, Alice T Shaw

Lancet Respir Med· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ALK-positive lung cancer: a moving target.
Jaime L Schneider, Jessica J Lin, Alice T Shaw

Nat Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer.
Julien Mazieres, Laura Iadeluca, Alice T Shaw, Benjamin J Solomon, Todd M Bauer

Lung Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Cabozantinib in Patients With Bone Metastasis.
Edwin Choy, Gregory M Cote, M Dror Michaelson, Lori Wirth, Justin F Gainor, Alice Shaw

Oncologist· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib.
Jaime L Schneider, Alona Muzikansky, Jessica J Lin, Elizabeth A Krueger, Inga T Lennes, Alice T Shaw

JTO Clin Res Rep· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.
Rafal Dziadziuszko, Solange Peters, Tony Mok, D Ross Camidge, Shirish M Gadgeel, Alice T Shaw

Clin Cancer Res· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse.
Ibiayi Dagogo-Jack, Geoffrey R Oxnard, Makenzi Evangelist, Subba R Digumarthy, Jessica J Lin, Alice T Shaw

JCO Precis Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease.
Sai-Hong I Ou, Benjamin J Solomon, Alice T Shaw, Shirish M Gadgeel, Benjamin Besse

J Thorac Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer.
Benjamin J Solomon, Todd M Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Alice T Shaw

Future Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms.
Haichuan Hu, Zofia Piotrowska, Patricia J Hare, Huidong Chen, Hillary E Mulvey, Alice T Shaw

Cancer Cell· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Taletrectinib (AB-106/DS-6051b) in NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies.
Sai-Hong Ignatius Ou, Yutaka Fujiwara, Alice T Shaw, Noboru Yamamoto, Kazuhiko Nakagawa

JTO Clin Res Rep· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis